Chimeric Bacteriocins Broaden Pseudomonas Activity Spectrum
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bacteriocins have limited activity spectrum and are highly specific against Pseudomonas strains, making them ineffective against unknown or unidentified pathogenic agents.
Innovation Solution
Development of chimeric antibacterial proteins by fusing the cytotoxic pore-forming domains of different Pseudomonas bacteriocins with the receptor-binding and translocation domains of pyocin S5, broadening their specificity and activity range.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural pyocins are used for treatment, then specific activity against Pseudomonas strains is achieved, but the activity spectrum is limited and specificity is high
Solution Approach 1:
The bacteriocin is divided into functional segments: a receptor-binding domain (first polypeptide segment) and a cytotoxic pore-forming domain (second polypeptide segment). By segmenting the protein and allowing independent selection of domains from different pyocins, the invention creates chimeric bacteriocins that combine the advantages of each segment while overcoming the limitations of natural pyocins.
Solution Approach 2:
The invention creates a universal receptor-binding domain that can recognize multiple Pseudomonas strains, while maintaining diverse cytotoxic domains from different pyocins. This multi-functionality allows a single bacteriocin structure to target multiple bacterial strains, expanding the activity spectrum while preserving specific cytotoxic activity.
2Adaptability or versatility
If chimeric bacteriocins are constructed with broad specificity, then activity against multiple strains is achieved, but protein structure complexity increases
Solution Approach 1:
By segmenting the bacteriocin into distinct functional domains (receptor-binding and cytotoxic), the invention simplifies the design process. Each segment can be independently selected and optimized, reducing the overall structural complexity compared to creating entirely new bacteriocins from scratch while achieving broad specificity.
Solution Approach 2:
The invention merges conserved functional elements from different natural pyocins into a single chimeric structure. By combining the receptor-binding domain of one pyocin with cytotoxic domains from multiple other pyocins, the invention achieves broad specificity without requiring completely new protein structures, thus managing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric bacteriocins demonstrate high cytotoxic activity and broadened specificity against multiple Pseudomonas strains, effectively reducing bacterial numbers in liquid culture, biofilm assays, and animal disease models.
Implementation Method 1
The only so far known P. aeruginosa pore-forming pyocin, S5, was found to be active against 40% of tested clinical isolates. S5 demonstrated superior activity compared to all other pyocins in reducing bacterial numbers in liquid culture and biofilm assays
Data Source
AI summary
The invention provides an antibacterial protein (bacteriocin) for the control of Pseudomonas, preferably of Pseudomonas aeruginosa, and to a nucleic acid molecule encoding the bacteriocin. The invention also relates to a composition, notably a pharmaceutical composition, comprising the bacteriocin or a combination of the bacteriocins. The invention further relates to the bacteriocin or composition for use in therapy.